, FcεRIIFDC-negative patients (poor prognosis). These 3 groups significantly differ (p = 0.000) both in OS and in PFS. This is the first evidence of the possibility to assess tumor behavior and treatment results in FL according to lymphoma biochemical and other than clinical parameters.
Introduction
Follicular lymphoma (FL) is a most frequent hemopoietic tumor in adults. It is characterized by an indolent course and a rather favorable outcome. However, in some cases the tumor fails to respond to therapy, and demonstrates resistance, rapid recurrence and has a fatal outcome.
FL prognostic patterns are based on international prognostic indices (IPI) including FL specific FLIPI-1 and -2. These indices take into account degree of lymph node and bone marrow involvement, the presence and number of extranodal sites, anemia, increased serum lactate dehydrogenase levels and advanced age in some of them. Basing on the indices the patients are divided into risk groups and receive treatment accordingly [1] . Over the last 15 years, the treatment has included monoclonal antibody to CD20 as a mandatory component.
Choice of treatment policy is mainly based on the prognostic indices and morphological findings which distinguish tumors with different cellular content (as required by the 2008 WHO classification), growth pattern and proliferative activity. Mandatory criteria include confirmed mature B-cell nature of the tumor, CD20 expression, and if needing additional markers (bcl-2, bcl-6, MUM-1), B-cell clonality and other criteria are used. FL originates from immunity cells, peripheral B-lymphocytes of lymph node follicular centers. These cells are referred to as centroblasts and centrocytes. As a whole the tumor content is polymorphous with T-cells, macrophages, follicular dendritic cells (FDCs) found within malignant germinal centers besides B-cells. At the beginning of the 21st century the investigators paid attention to the fact that this hemopoietic tissue tumor was in many respects regulated by cells of so called non-tumor environment, i.e. T-lymphocytes and macrophages [2] . Infiltration of tumor tissue by immune cells was reflected by gene expression profiles in the tumor tissue. Two types of immune response were defined accordingly that were associated with microenvironment cells infiltrating the tumor. Type 1 immune response was due to T-lymphocytes and had a good prognosis. While immune response type 2 was associated with macrophages and poor prognosis. It was shown later that implementation of immune response in germinal centers involves (besides T-helpers, follicular T-helpers) T-regulatory cells that could produce a positive effect in FL owing to specific features of the regulation or B-cell response. While macrophages had a reverse effect, that was counteracted by rituximab. Assessment of gene expression profiles was not widely used in clinical practice because the procedure was too labor-consuming, and surrogate markers of microenvironment were not utilized due to poor data reproducibility and not clear clinical significance.
This paper evaluates the role of non-tumor microenvironment in FL that is FDCs expressing Fc-epsilon receptor II referred to as CD23 according to the differentiation antigen nomenclature.
Materials and Methods
The investigation was made at the N. Statistical analysis of study results included comparison of means, non-parametric data were analyzed using contingency tables and Pearson's chi squared test (1990) . Significance of the effect of prognostic factors on patients' survival and response duration was ere assessed using Cox regression.
Results
Immunohistochemical identification of CD23+ FDCs in FL tissue was made in 232 patients with 87.5% of positive tests ( Table 1 ).
The positive tests included all cases with tumor tissue FDCs as areas of hyperplasia, loose areas and remaining groups of FDCs.
Since CD23 is used to identify FDCs of follicular clear centers, it was not unexpected to find that the presence of CD23+ FDCs correlated highly with nodular growth pattern in FL, p = 0.000 (Table 2) .
CD23+ FDCs were found in next to 100% of tumors with nodular growth against 58.3% of those with diffuse growth.
The presence of CD23+ FDCs was found not related with FL cytology (p = 0.45).
There was no association between CD23+ FDCs and clinical prognostic factors such as patient age above 60 years (p = 0.2), the number of FLIPI poor prognosis criteria (p = 0.72), FLIPI risk groups (p = 0.9), IPI prognostic factors (p = 0.77) or IPI risk groups (p = 0.55).
Disease stage was not associated with the presence of CD23+ FDCs either (p = 0.55).
We failed to find association with ECOG performance status (p = 0.37), intoxication symptoms (p = 0.7) or elevated Lactat Dehydrogenase (LDH) levels (p = 0.73). Basing on these findings the conclusion may be made that the presence of FDCs (CD23+) in the tumor tissue is an important factor of good prognosis in FL.
However, if hematogenic dissemination occurs as most fully reflected by bone Recent study data confirm most convincingly that FDCs may originate from bone marrow stromal progenitors [7] . These studies also confirm findings of earlier experimental investigations [8] . FDCs emerge in bone marrow from STRO-1+ bone marrow cells forming fibroblast colonies and are similar or identical to mesenchymal stem cells. These progenitors migrate from the bone marrow into secondary lymphoid organs and differentiate into certain lineages.
Discussion and Conclusion
Some authors believe FDCs to play the central role in lymphoid tissues [9] .
In order to better understand the role of CD23+ FDCs, one has to consider processes occurring in germinal centers of lymph node follicles. Microenviron- So, the immunomorphological characteristic with a well known functional role receptor may be added to the FLIPI prognostic factors, which are listed in recent ESMO guidelines [13] .
